Clinical Trial: NCT04489771
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
Official Title
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
Conditions
Carcinoma, Renal Cell
Intervention / Treatment
- Drug: Belzutifan
Other Study ID Numbers
- 6482-013
- MK-6482-013
- 2022-502123-21-00
- U1111-1283-3731
- 2020-001907-18
Start Date (Actual)
2020-09-13
Primary Completion Date (Actual)
2023-02-10
Study Completion Date (Actual)
2026-08-25
Enrollment (Actual)
154
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
Official Title
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
Conditions
Carcinoma, Renal Cell
Intervention / Treatment
- Drug: Belzutifan
Other Study ID Numbers
- 6482-013
- MK-6482-013
- 2022-502123-21-00
- U1111-1283-3731
- 2020-001907-18
Start Date (Actual)
2020-09-13
Primary Completion Date (Actual)
2023-02-10
Study Completion Date (Actual)
2026-08-25
Enrollment (Actual)
154
Study Type
Interventional
Phase
Phase 2